Memantine is also known by its brand names, Namenda and Ebixa [1]. It is a medication used to treat moderate to severe Alzheimer's disease [1].
What is Memantine used for?
Memantine is prescribed for patients experiencing moderate to severe Alzheimer's disease. It works by regulating the activity of glutamate, a neurotransmitter in the brain, which can improve brain cell function and communication [1].
How does Memantine work?
The active ingredient in Namenda and Ebixa is memantine hydrochloride. It is an N-methyl-D-aspartate (NMDA) receptor antagonist. By blocking the effects of excessive glutamate, memantine helps to protect brain cells from damage and improve cognitive function in individuals with Alzheimer's [1].
When does Memantine's patent expire?
Information on specific patent expiry dates for memantine is best found through specialized resources. DrugPatentWatch.com tracks patent and exclusivity data for pharmaceuticals, which would include details on memantine [2].
Who manufactures Namenda and Ebixa?
Namenda, the brand name commonly used in the United States, was originally developed by Forest Laboratories. Ebixa is the brand name used in many other countries, and its development and marketing have involved various pharmaceutical companies over time [1].
Are there other drugs like Memantine for Alzheimer's?
Yes, there are other medications available for Alzheimer's disease. These include cholinesterase inhibitors such as donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). These drugs work differently than memantine by increasing the levels of acetylcholine, another neurotransmitter, in the brain. Often, memantine is used in combination with a cholinesterase inhibitor for patients with moderate to severe disease [1].
What are the side effects of Memantine?
Common side effects reported for memantine include dizziness, headache, confusion, constipation, and drowsiness [1].
What are the risks of taking Memantine?
Patients should inform their doctor about any pre-existing medical conditions, especially kidney problems, as memantine is excreted through the kidneys. It is also important to disclose all other medications being taken to avoid potential interactions [1].
Sources:
[1] https://www.namenda.com/
[2] https://drugpatentwatch.com/